Guest: Muthiah Vaduganathan, MD, MPH

Guest: Anuradha Lala-Trindade, MD

Guest: Brendon Neuen, MBBS, PhD

Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date!

Guest: Anuja Java, MD

With the recent approval of iptacopan and promising data on pegcetacoplan emerging, targeted therapy is becoming a reality for patients with complement 3 glomerulopathy (C3G). Hear from Dr. Gates Colbert and Dr. Anuja Java as they dive into the details of newer treatments, key considerations for patient monitoring, and the role of precision medicine in patient care. Dr. Java is an Assistant Professor of Medicine in the Division of Nephrology at Washington University School of Medicine and the Director of the Kidney Transplant Clinic at John Cochran Veterans Hospital in Missouri.

Guest: Anuja Java, MD

Complement 3 glomerulopathy (C3G) presents complex diagnostic hurdles due to its rarity, clinical heterogeneity, and lack of definitive biomarkers. Tune in to hear Dr. Gates Colbert and Dr. Anuja Java discuss the need for improved biomarker development, our evolving understanding of complement dysregulation, and the importance of multidisciplinary awareness in advancing timely and accurate diagnosis. Dr. Java is an Associate Professor of Medicine in the Division of Nephrology at Washington University School of Medicine and the Director of the Kidney Transplant Clinic at John Cochran Veterans Hospital in Missouri.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Jonathan Barratt, MD, PhD

New insights into B-cell dysregulation are reshaping our understanding of IgA nephropathy (IgAN), and the BAFF/APRIL pathway in particular is being studied for its role in driving immune complex formation, glomerular injury, and disease progression. Joining Dr. Charles Turck to discuss B-cell dysregulation and its potential impacts on the IgAN treatment landscape is Dr. Jonathan Barratt. Dr. Barratt is the Mayor Professor of Renal Medicine at the University of Leicester in the United Kingdom, where he also leads the Renal Research Group.

Host: Gates B. Colbert, MD

Guest: Meghan Sise, MD

Guest: Ellie Kelepouris, MD, FACP, FAHA

Early detection of IgA nephropathy (IgAN) is often missed due to its subtle presentation, leading to delays in critical care. However, knowing the red-flag signs and symptoms to look out for can help improve timely diagnosis and intervention. Joining Dr. Gates Colbert to discuss practical strategies for identifying IgAN early are Drs. Meghan Sise and Ellie Kelepouris. Dr. Sise is the Director of Onconephrology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, and Dr. Kelepouris is the Director of the Outpatient Dialysis Program and a Professor of Clinical Medicine at Penn Medicine.

Host: Brian P. McDonough, MD, FAAFP

Guest: Suneel Udani, MD

Over the past several decades, IgA nephropathy (IgAN) has gone from being regarded as relatively harmless to being recognized as a progressive, high-risk disease. With this new understanding, early diagnosis and strategic intervention are more critical than ever. Tune in as Dr. Suneel Udani, a nephrologist with Nephrology Associates of Northern Illinois, joins Dr. Brian McDonough to examine the key factors in detecting and treating IgAN.

Guest: Finnian R. McCausland, MD

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

Guest: prof. Hiddo Heerspink

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

Guest: Finnian R. McCausland, MD

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.